Dashboard
Manage Tickers

SVRASavara Inc

Nasdaq savarapharma.com


$ 4.19 $ -0.04 (-0.94 %)    

Friday, 13-Sep-2024 15:59:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 4.2
$ 4.26
$ 4.19 x 400
$ 4.21 x 500
$ 4.18 - $ 4.26
$ 3.12 - $ 5.70
657,625
na
691.32M
$ 0.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-07-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-30-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-11-2022 03-31-2022 10-Q
11 03-30-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-10-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-12-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-13-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 03-14-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-06-2017 12-31-2016 10-K
32 11-08-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-06-2016 03-31-2016 10-Q
35 03-14-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-12-2015 06-30-2015 10-Q
38 05-11-2015 03-31-2015 10-Q
39 03-24-2015 12-31-2014 10-K
40 10-31-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jmp-securities-reiterates-market-outperform-on-savara-maintains-9-price-target
JMP Securities Reiterates Market Outperfor...
09/09/2024 14:22:07

JMP Securities analyst Jonathan Wolleben reiterates Savara (NASDAQ:SVRA) with a Market Outperform and maintains $9 price tar...

why-summit-therapeutics-shares-are-trading-higher-by-around-18-here-are-20-stocks-moving-premarket
Why Summit Therapeutics Shares Are Trading...
09/09/2024 10:08:36

reported-sunday-savara-unveils-phase-3-impala-2-trial-data-on-molgramostim-for-autoimmune-pulmonary-alveolar-proteinosis-at-ers-congress-2024
Reported Sunday, Savara Unveils Phase 3 IM...
09/09/2024 07:45:07

Mean Change From Baseline in Disease Severity Score (DSS) Showed Significant Improvement with Molgramostim Compared with Plac...

savara-announces-acceptance-of-abstract-for-poster-presentation-at-european-respiratory-society-congress-2024-in-vienna-will-present-results-from-impala-2-study-on-inhaled-molgramostim-for-autoimmune-pulmonary-alveolar-proteinosis-and-sponsor-an-industry-symposium
Savara Announces Acceptance Of Abstract Fo...
08/15/2024 12:23:18

hc-wainwright--co-reiterates-buy-on-savara-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Sava...
08/14/2024 18:15:11

HC Wainwright & Co. analyst Andrew Fein reiterates Savara (NASDAQ:SVRA) with a Buy and maintains $10 price target.

jmp-securities-maintains-market-outperform-on-savara-lowers-price-target-to-9
JMP Securities Maintains Market Outperform...
08/13/2024 11:51:38

JMP Securities analyst Jonathan Wolleben maintains Savara (NASDAQ:SVRA) with a Market Outperform and lowers the price target...

savara-q2-2024-adj-eps-012-misses-011-estimate
Savara Q2 2024 Adj EPS $(0.12) Misses $(0....
08/12/2024 20:06:07

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9...

savara-announces-pricing-of-100m-underwritten-offering-of-common-stock-of-26246720-shares-of-its-common-stock-at-a-price-of-381-per-share
Savara Announces Pricing Of $100M Underwri...
06/28/2024 12:50:43

Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the...

guggenheim-maintains-buy-on-savara-raises-price-target-to-10
Guggenheim Maintains Buy on Savara, Raises...
06/27/2024 17:29:58

Guggenheim analyst Daniel Krizay maintains Savara (NASDAQ:SVRA) with a Buy and raises the price target from $8 to $10.

hc-wainwright--co-maintains-buy-on-savara-raises-price-target-to-10
HC Wainwright & Co. Maintains Buy on Savar...
06/27/2024 10:11:55

HC Wainwright & Co. analyst Andrew Fein maintains Savara (NASDAQ:SVRA) with a Buy and raises the price target from $6 to...

oppenheimer-maintains-outperform-on-savara-raises-price-target-to-15
Oppenheimer Maintains Outperform on Savara...
06/26/2024 17:30:37

Oppenheimer analyst Francois Brisebois maintains Savara (NASDAQ:SVRA) with a Outperform and raises the price target from $11...

why-is-respiratory-disease-focused-savara-stock-trading-higher-on-wednesday
Why Is Respiratory Disease-Focused Savara ...
06/26/2024 13:36:38

Savara announces Phase 3 IMPALA-2 trial results for molgramostim in treating autoimmune pulmonary alveolar proteinosis. The inh...

savara-shares-are-trading-higher-after-the-company-announced-the-phase-3-impala-2-clinical-trial-met-its-primary-endpoints-and-multiple-scondary-endpoints
Savara shares are trading higher after the...
06/26/2024 11:42:11

savara-inc-announces-phase-3-trial-results-for-molgramostim-in-treating-rare-respiratory-disease
Savara Inc Announces Phase 3 Trial Results...
06/26/2024 10:33:16

Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today...

savaras-phase-3-impala-2-trial-of-molgramostim-met-statistical-significance-for-primary-endpoint-and-multiple-secondary-endpoints-in-autoimmune-pulmonary-alveolar-proteinosis
Savara's Phase 3 IMPALA-2 Trial Of Molgram...
06/26/2024 10:33:03

Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus ...

oppenheimer-maintains-outperform-on-savara-raises-price-target-to-11
Oppenheimer Maintains Outperform on Savara...
05/21/2024 11:59:29

Oppenheimer analyst Francois Brisebois maintains Savara (NASDAQ:SVRA) with a Outperform and raises the price target from $9....

reported-sunday-savara-and-trillium-health-presented-new-data-on-autoimmune-pulmonary-alveolar-proteinosis-at-ats-2024
Reported Sunday, Savara And Trillium Healt...
05/20/2024 05:46:10

Below are summaries of the posters presented: Poster Board 701: "Healthcare Burden of Pulmonary Alveolar Proteinosis" ...

evercore-isi-group-maintains-outperform-on-savara-lowers-price-target-to-7
Evercore ISI Group Maintains Outperform on...
05/16/2024 17:01:03

Evercore ISI Group maintains Savara (NASDAQ:SVRA) with a Outperform and lowers the price target from $10 to $7.

hc-wainwright--co-reiterates-buy-on-savara-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Sava...
05/13/2024 10:41:18

HC Wainwright & Co. analyst Andrew Fein reiterates Savara (NASDAQ:SVRA) with a Buy and maintains $6 price target.

savara-q1-2024-adj-eps-011-misses-010-estimate
Savara Q1 2024 Adj EPS $(0.11) Misses $(0....
05/09/2024 21:01:00

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 1...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION